📰 Equitis Gestion News
Equitis Gestion News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Equitis Gestion. Real-time updates on events, politics, business and more.
March 12, 2024
Not for publication, release, or distribution directly or indirectly in the United States, Canada, Australia or Japan.This press release is not an advertisement nor a prospectus within the meaning of...
April 20, 2023
Societe Generale is launching an Ethereum-based euro stablecoin through its dedicated digital asset arm, Societe Generale-Forge.
April 20, 2023
Societe Generale-Forge (SG-Forge) on April 20 announced the launch of EUR CoinVertible, a euro-pegged stablecoin.
January 2, 2023
Entering into an amendment to the trust agreement Dardilly, January 2, 2023 – 7pm As part of the preparation of the next General Assembly, the Board of...
October 31, 2022
DJ Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th
October 31, 2022
DJ Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th
October 3, 2022
DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement
October 3, 2022
DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement
October 3, 2022
DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement
October 3, 2022
DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement